PMID- 35907001
OWN - NLM
STAT- MEDLINE
DCOM- 20230106
LR  - 20230111
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 280
IP  - 1
DP  - 2023 Jan
TI  - PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line 
      treatment for recurrent or metastatic head and neck squamous cell carcinoma.
PG  - 1-9
LID - 10.1007/s00405-022-07571-9 [doi]
AB  - OBJECTIVE: This study aimed to evaluate the efficacy and safety of programmed 
      cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitor plus 
      chemotherapy vs standard of care (SoC) treatment in the first-line treatment for 
      recurrent or metastatic head and neck squamous cell carcinoma (R/M-SCCHN). 
      METHODS: Randomized controlled trials (RCTs) that investigated PD-1/PD-L1 
      inhibitor plus chemotherapy vs SoC as first-line treatment for R/M-SCCHN were 
      searched from electronic databases (PubMed, Embase and Cochrane Library). The 
      primary outcomes were overall survival (OS), progression-free survival (PFS), 
      objective response rate (ORR), and adverse events (AEs). RESULTS: In total, three 
      phase 3 RCTs (KEYNOTE-048, CAPTAIN-1st, and JUPITER-02; n = 1120) with three PD-1 
      inhibitors (pembrolizumab, camrelizumab and toripalimab) were included in the 
      analysis. Compared with SoC, PD-1 inhibitor plus chemotherapy significantly 
      prolonged PFS (hazard ratio [HR] 0.66, 95% CI 0.40-0.93, p < 0.001) and OS (HR 
      0.73, 95% CI 0.60-0.86, p < 0.001) of patients. There was no statistical 
      differences in ORR (odds ratio [OR] 1.26; 95% CI 0.97-1.64, p = 0.086), grade 3 
      or higher AEs (OR 0.77, 95% CI 0.50-1.17, p = 0.221), and treatment-related 
      deaths (OR 1.34, 95% CI 0.60-2.98, p = 0.470) between the two groups. CONCLUSION: 
      PD-1 inhibitor plus chemotherapy showed more survival benefit than SoC in the 
      first-line treatment for R/M-SCCHN, with a similar safety profile.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Mo, Dun-Chang
AU  - Mo DC
AUID- ORCID: 0000-0003-1316-2810
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Dan-Cun Road No.13, Nanning, 530000, Guangxi, China. 
      modunchang2018@163.com.
FAU - Huang, Jian-Feng
AU  - Huang JF
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Dan-Cun Road No.13, Nanning, 530000, Guangxi, China.
FAU - Luo, Peng-Hui
AU  - Luo PH
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Dan-Cun Road No.13, Nanning, 530000, Guangxi, China.
FAU - Chen, Long
AU  - Chen L
AD  - ENT & HN Surgery Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, 530000, Guangxi, China.
FAU - Zou, Biao
AU  - Zou B
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Dan-Cun Road No.13, Nanning, 530000, Guangxi, China.
FAU - Wang, Han-Lei
AU  - Wang HL
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Dan-Cun Road No.13, Nanning, 530000, Guangxi, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220730
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (B7-H1 Antigen)
SB  - IM
MH  - Humans
MH  - Squamous Cell Carcinoma of Head and Neck/drug therapy
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - Programmed Cell Death 1 Receptor/therapeutic use
MH  - Standard of Care
MH  - *Antineoplastic Agents, Immunological/therapeutic use
MH  - *Head and Neck Neoplasms/drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - B7-H1 Antigen/metabolism
MH  - *Lung Neoplasms/pathology
OTO - NOTNLM
OT  - Efficacy and safety
OT  - Head and neck squamous cell carcinoma
OT  - Meta-analysis
OT  - Programmed cell death-1/programmed cell death-ligand 1
EDAT- 2022/07/31 06:00
MHDA- 2023/01/07 06:00
CRDT- 2022/07/30 11:12
PHST- 2022/07/01 00:00 [received]
PHST- 2022/07/22 00:00 [accepted]
PHST- 2022/07/31 06:00 [pubmed]
PHST- 2023/01/07 06:00 [medline]
PHST- 2022/07/30 11:12 [entrez]
AID - 10.1007/s00405-022-07571-9 [pii]
AID - 10.1007/s00405-022-07571-9 [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2023 Jan;280(1):1-9. doi: 10.1007/s00405-022-07571-9. 
      Epub 2022 Jul 30.